首页|某三甲医院1019例药品不良反应报告分析

某三甲医院1019例药品不良反应报告分析

Analysis of 1 019 cases of adverse drug reaction reports from a certain ter-tiary hospital

扫码查看
目的 探究本院药品不良反应(ADR)的发生特点,为临床合理用药提供参考.方法 回顾性收集本院2020年1月-2023年9月上报国家药品不良反应监测中心的ADR报告,分析发生ADR的患者性别、年龄、给药途径、ADR类型、涉及药品种类、ADR累及器官/系统及主要临床表现等.结果 共收集1019例ADR报告,其中一般类型的ADR 761例(74.68%),严重的ADR 213例(20.90%),新的ADR 45例(4.42%);静脉滴注给药引起的ADR最多(52.11%);引起ADR的药物种类前3位的分别为抗肿瘤药物(46.29%)、抗感染药物(16.95%)、代谢及内分泌系统用药(7.17%);ADR累及器官/系统以胃肠系统损害最为常见(21.87%),其次为血液系统损害(16.14%)、皮肤及其附件损害(16.14%).严重的ADR主要表现为骨髓抑制(47.00%).结论 临床应加强静脉用药、抗肿瘤药物及抗感染药物的监管,重视ADR监测和上报工作,促进合理用药.
Objective To explore the characteristics of adverse drug reactions(ADR)in our hospital,and to provide references for rational drug use in clinical practice.Methods The ADR reports submitted to the National Adverse Drug Re-action Monitoring Center from January 2020 to September 2023 were retrospectively collected,and the gender,age,route of administration,type of ADR,types of drugs involved,organs/systems involved in ADR,and main clinical manifestations of the patients with ADR were analyzed.Results A total of 1 019 ADR reports were collected,including 761 cases(74.68%)of general type ADR,213 cases(20.90%)of severe ADR,and 45 cases(4.42%)of new ADR,with the highest number of ADRs caused by intravenous infusion administration(52.11%).The top three drugs that caused ADR were antitumor drugs(46.29%),anti-infective drugs(16.95%),and metabolic and endocrine system drugs(7.17%).Gastrointestinal system damage was the most common(21.87%),followed by hematologic system damage(16.14%),and skin and appendage damage(16.14%).Severe ADR was mainly manifested as bone marrow suppression(47.00%).Conclusion The clinical supervision of intravenous drug use,anti-tumor drugs,and anti-infective drugs should be strengthened,attention should be paid to ADR monitoring and reporting,and rational drug use should be promoted.

Adverse drug reactionRational drug useDrug safety

张亚飞、操艺、王媛媛

展开 >

安徽医科大学第二附属医院药学部,安徽合肥 230601

药品不良反应 合理用药 用药安全

安徽医科大学校科研基金立项资助项目

2022xkj043

2024

中国校医
江苏省预防医学会 中华预防医学会

中国校医

影响因子:0.378
ISSN:1001-7062
年,卷(期):2024.38(4)
  • 12